Published in J Pediatr on February 05, 2014
Middle-School Based Primary Prevention Trial of Type 2 Diabetes (HEALTHY) | NCT00458029
Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. Int J Obes (Lond) (2016) 0.76
Sex differences in the associations of visceral adiposity, homeostatic model assessment of insulin resistance, and body mass index with lipoprotein subclass analysis in obese adolescents. J Clin Lipidol (2016) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lipid screening and cardiovascular health in childhood. Pediatrics (2008) 6.62
Adolescent overweight and future adult coronary heart disease. N Engl J Med (2007) 5.74
A school-based intervention for diabetes risk reduction. N Engl J Med (2010) 4.71
Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr (2009) 3.90
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes (2003) 2.79
Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol (1991) 2.52
Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol (2002) 2.38
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care (2004) 2.25
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation (2005) 2.21
Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr (2011) 2.01
Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism (2005) 1.77
Social marketing-based communications to integrate and support the HEALTHY study intervention. Int J Obes (Lond) (2009) 1.69
Rationale, design and methods of the HEALTHY study nutrition intervention component. Int J Obes (Lond) (2009) 1.65
Rationale, design and methods of the HEALTHY study behavior intervention component. Int J Obes (Lond) (2009) 1.61
Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes (2010) 1.52
Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model. Am J Public Health (2009) 1.38
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res (2000) 1.25
Sensitivity, specificity, and predictive values of pediatric metabolic syndrome components in relation to adult metabolic syndrome: the Princeton LRC follow-up study. J Pediatr (2007) 1.18
Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis (1990) 1.17
Shifts in BMI category and associated cardiometabolic risk: prospective results from HEALTHY study. Pediatrics (2012) 1.12
Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab (2013) 1.09
Factors affecting the stability of blood lipid and lipoprotein levels from youth to adulthood: evidence from the Childhood Determinants of Adult Health Study. Arch Pediatr Adolesc Med (2011) 1.01
Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol (2012) 1.00
HEALTHY intervention: fitness, physical activity, and metabolic syndrome results. Med Sci Sports Exerc (2011) 0.96
Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J Clin Endocrinol Metab (2011) 0.94
The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord (2004) 0.92
Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. Atherosclerosis (2009) 0.92
Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis (2009) 0.91
The HEALTHY study: introduction. Int J Obes (Lond) (2009) 0.90
Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size. Atherosclerosis (2005) 0.86
Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Relat Disord (2012) 0.84
Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. Pediatr Obes (2012) 0.84
Prediabetic obese adolescents have a more atherogenic lipoprotein profile compared with normoglycemic obese peers. J Pediatr (2012) 0.83
Relation of long-term body weight change to change in lipoprotein particle size in Japanese men and women: the INTERMAP Toyama Study. Atherosclerosis (2009) 0.82
Can lipid and lipoprotein concentrations in childhood predict adult atherosclerosis? J Am Coll Cardiol (2009) 0.81
Beyond cholesterol: the atherogenic consequences of combined dyslipidemia. J Pediatr (2012) 0.80
Low-density lipoprotein cholesterol versus particle number in middle school children. J Pediatr (2013) 0.80
Lipid plasma concentrations of HDL subclasses determined by enzymatic staining on polyacrylamide electrophoresis gels in children with metabolic syndrome. Clin Chim Acta (2010) 0.79
A school-based intervention for diabetes risk reduction. N Engl J Med (2010) 4.71
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care (2015) 3.80
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20
HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. Int J Obes (Lond) (2009) 2.15
Rationale, design and methods for process evaluation in the HEALTHY study. Int J Obes (Lond) (2009) 1.70
Social marketing-based communications to integrate and support the HEALTHY study intervention. Int J Obes (Lond) (2009) 1.69
Rationale, design and methods of the HEALTHY study nutrition intervention component. Int J Obes (Lond) (2009) 1.65
Rationale, design and methods of the HEALTHY study physical education intervention component. Int J Obes (Lond) (2009) 1.61
Rationale, design and methods of the HEALTHY study behavior intervention component. Int J Obes (Lond) (2009) 1.61
Risk factors for type 2 diabetes in a sixth- grade multiracial cohort: the HEALTHY study. Diabetes Care (2009) 1.44
Recruitment and retention strategies and methods in the HEALTHY study. Int J Obes (Lond) (2009) 1.20
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care (2015) 1.12
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care (2014) 1.07
Process evaluation results from the HEALTHY physical education intervention. Health Educ Res (2011) 1.02
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2016) 0.97
The effects of the HEALTHY study intervention on middle school student dietary intakes. Int J Behav Nutr Phys Act (2011) 0.95
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. Diabetes Care (2015) 0.91
Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care (2015) 0.90
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care (2015) 0.89
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J (2016) 0.88
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care (2015) 0.85
Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. Pediatr Obes (2012) 0.84
Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care (2012) 0.81
School factors as barriers to and facilitators of a preventive intervention for pediatric type 2 diabetes. Transl Behav Med (2014) 0.80
Low-density lipoprotein cholesterol versus particle number in middle school children. J Pediatr (2013) 0.80
The War Is Not Yet Won. Diabetes Care (2017) 0.75
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care (2016) 0.75
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. Diabetes Care (2017) 0.75
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care (2017) 0.75
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care (2017) 0.75
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care (2019) 0.75